# Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells

> **NCT06491043** · PHASE2 · RECRUITING · sponsor: **Meribank Biotech Co., Ltd.** · enrollment: 90 (estimated)

## Conditions studied

- Chronic Obstructive Pulmonary Disease

## Interventions

- **OTHER:** UMC119-06-05

## Key facts

- **NCT ID:** NCT06491043
- **Lead sponsor:** Meribank Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-11
- **Primary completion:** 2026-12-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2024-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06491043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06491043, "Treatment of Chronic Obstructive Pulmonary Disease by Infusion of Allogenic Mesenchymal Stem Cells". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06491043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*